BCL9 is highly expressed in clinical prostate specimens in comparison to the benign prostate tissues.392 In prostate cancer group, the positive rate of BCL9 was 53.1% (52/98), whereas in benign group the positivity rate was 25.0% (5/20; P = 0.022). Here, BCL9 is linked to prostate carcinoma.